Literature DB >> 19000143

Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study.

D Hauzenberger1, M Schaffer, O Ringdén, Z Hassan, B Omazic, J Mattsson, A-C Wikström, M Remberger.   

Abstract

We studied the importance of human leucocyte antigen (HLA)-A, -B and -DRB1 high-resolution matching on the outcome of haematopoietic stem cell transplantation (HSCT) with matched unrelated donors (MUDs) vs single allele-mismatched unrelated donors. Fifty consecutive HSCT patients receiving an HLA-A, -B or -DR allele-level-mismatched unrelated graft (mmUD) were compared with a matched cohort of 100 patients with an HLA-A, -B and -DR-MUD. Rejection occurred in seven patients (14%) in the mmUD group and in four patients (4%) in the MUD group (P = 0.04), but this was mainly an effect of HLA-C mismatch. The cumulative incidence of acute graft vs host disease (GVHD) grades II-IV were 61%, 26% and 33% in the class I mmUD, class II mmUD and MUD groups, respectively. In multivariate analysis, HLA class I mismatch was associated with an increased risk of acute GVHD grades II-IV (2.09, P = 0.007) and transplant-related mortality (TRM) (1.99, P = 0.06). The 5-year overall survival was 81% in patients with a class II allele-mismatched donor compared with 52% (P = 0.025) and 50% (P = 0.017) in patients with a class I mismatch and a MUD. In multivariate analysis, HLA class II allele mismatch was associated with improved survival (3.38, P = 0.019). Relapse-free survival were 53%, 37% and 42% in patients with a class II mmUD, class I mmUD and a MUD, respectively (not significant). An HLA-C or -DQ mismatch had no significant impact on survival, TRM and relapse. In conclusion, compared with MUD, HLA class I allele mmUD had an increased risk of acute GVHD and TRM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19000143     DOI: 10.1111/j.1399-0039.2008.01148.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  5 in total

1.  Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.

Authors:  Rohtesh S Mehta; Shernan G Holtan; Tao Wang; Michael T Hemmer; Stephen R Spellman; Mukta Arora; Daniel R Couriel; Amin M Alousi; Joseph Pidala; Hisham Abdel-Azim; Vaibhav Agrawal; Ibrahim Ahmed; A Samer Al-Homsi; Mahmoud Aljurf; Joseph H Antin; Medhat Askar; Jeffery J Auletta; Vijaya Raj Bhatt; Lynette Chee; Saurabh Chhabra; Andrew Daly; Zachariah DeFilipp; James Gajewski; Robert Peter Gale; Usama Gergis; Peiman Hematti; Gerhard C Hildebrandt; William J Hogan; Yoshihiro Inamoto; Rodrigo Martino; Navneet S Majhail; David I Marks; Taiga Nishihori; Richard F Olsson; Attaphol Pawarode; Miguel Angel Diaz; Tim Prestidge; Hemalatha G Rangarajan; Olle Ringden; Ayman Saad; Bipin N Savani; Hélène Schoemans; Sachiko Seo; Kirk R Schultz; Melhem Solh; Thomas Spitzer; Jan Storek; Takanori Teshima; Leo F Verdonck; Baldeep Wirk; Jean A Yared; Jean-Yves Cahn; Daniel J Weisdorf
Journal:  J Clin Oncol       Date:  2020-05-04       Impact factor: 44.544

2.  Shedding a new light on the HLA matching.

Authors:  Hye Lim Jung
Journal:  Korean J Hematol       Date:  2011-03-15

3.  Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation.

Authors:  S R Marino; S Lin; M Maiers; M Haagenson; S Spellman; J P Klein; T A Binkowski; S J Lee; K van Besien
Journal:  Bone Marrow Transplant       Date:  2011-03-28       Impact factor: 5.483

4.  Understanding the obstacle of incompatibility at residue 156 within HLA-B*35 subtypes.

Authors:  Trishna Manandhar; Heike Kunze-Schumacher; Trevor Huyton; Alexander A Celik; Rainer Blasczyk; Christina Bade-Doeding
Journal:  Immunogenetics       Date:  2016-01-12       Impact factor: 2.846

5.  Stem cell transplantation during cancer.

Authors:  Xiao-Ying Zhang; Pei-Ying Zhang
Journal:  Oncol Lett       Date:  2016-10-13       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.